clinical trial · NCT07161544
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
Stargardt DiseaseAAVB-039
brief summary
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
started
Sep 29, 2025
primary completion
Jul 1, 2032
completion
Jul 1, 2032
last updated
May 29, 2026
official title
An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants With Stargardt Disease (STGD1) (CELESTE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol